Search

Author/Creator Mous, Rogier

2. Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib. Issue 14 (5th December 2020)

Authors:
Svanberg, Rebecka; Ostrowski, Sisse Rye; Nasserinejad, Kazem; Kersting, Sabina; Dobber, Johan A.; Mattson, Mattias; Tran, Hoa T. T.; Levin, Mark-David; Mous, Rogier; Kater, Arnon P.; Niemann, Carsten U.
Journal:
Leukemia & lymphoma
Issue:
Volume 61:Issue 14(2020)
Page Start:
3422
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. Issue 10 (24th August 2022)

Authors:
Raa, Doreen G. Te; van der Straten, Lina; van Gelder, Michel; Kersting, Sabina; Levin, Mark-David; Mous, Rogier; van der Straaten, Hanneke M.; Nijziel, Marten R.; van der Spek, Ellen; Posthuma, Eduardus F. M; Visser, Hein P.J; van der Klift, Marjolein; de Heer, Koen; Bellido, Mar; Doorduijn, Jean...
Journal:
Leukemia & lymphoma
Issue:
Volume 63:Issue 10(2022)
Page Start:
2276
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Issue 10306 (25th September 2021)

Authors:
Hutchings, Martin; Mous, Rogier; Clausen, Michael Roost; Johnson, Peter; Linton, Kim M; Chamuleau, Martine E D; Lewis, David John; Sureda Balari, Anna; Cunningham, David; Oliveri, Roberto S; Elliott, Brian; DeMarco, Dena; Azaryan, Ada; Chiu, Christopher; Li, Tommy; Chen, Kuo-mei; Ahmadi, Tahamtan...
Journal:
Lancet
Issue:
Volume 398:Issue 10306(2021)
Page Start:
1157
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational study. Issue 12 (22nd October 2019)

Authors:
Ruchlemer, Rosa; Ben‐Ami, Ronen; Bar‐Meir, Maskit; Brown, Jennifer R.; Malphettes, Marion; Mous, Rogier; Tonino, Sanne H.; Soussain, Carole; Barzic, Noelie; Messina, Julia A.; Jain, Preetesh; Cohen, Regev; Hill, Brian; Mulligan, Stephen P.; Nijland, Marcel; Herishanu, Yair; Benjamini, Ohad; Tadmo...
Journal:
Mycoses
Issue:
Volume 62:Issue 12(2019)
Page Start:
1140
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Issue 6 (June 2022)

Authors:
Kater, Arnon P; Levin, Mark-David; Dubois, Julie; Kersting, Sabina; Enggaard, Lisbeth; Veldhuis, Gerrit J; Mous, Rogier; Mellink, Clemens H M; van der Kevie-Kersemaekers, Anne-Marie F; Dobber, Johan A; Poulsen, Christian B; Frederiksen, Henrik; Janssens, Ann; Schjødt, Ida; Dompeling, Ellen C; Ran...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 6(2022)
Page Start:
818
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗